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Objectives: Abiraterone acetate and enzalutamide, novel anti-androgen therapies 
with distinct modes of action for the treatment of metastatic castration-resistant 
prostate cancer (mCRPC), are approved in both the pre-chemotherapy and post-
chemotherapy settings. These anti-androgen therapies have significantly improved 
outcomes among mCRPC patients. However, to date there is little published evidence 
regarding patients’ real-world experience of these therapies in both the pre-chem-
otherapy or post-chemotherapy settings, particularly in terms of health-related 
quality of life (HRQoL) and treatment satisfaction. MethOds: Qualitative face-to-
face interviews were conducted with mCRPC patients (n= 38) and carers (n= 12) to 
obtain in-depth data concerning the patient experience with novel anti-androgen 
therapy. This included patients with experience of abiraterone acetate or enzalu-
tamide in either the pre-chemotherapy or post-chemotherapy setting in France, 
Germany and the UK. Findings from this study have been used to inform the design 
of a larger quantitative, multinational online survey to further explore and quantify 
HRQoL and treatment satisfaction among mCRPC patients receiving anti-androgen 
therapy. Results: Patients generally had high expectations at initiation of ther-
apy with a primary emphasis on reduction in prostate-specific antigen levels and 
improvements in HRQoL. Patients and carers reported that experiences on treat-
ment had met or exceeded expectations. Administration procedures appeared to 
be of limited concern for patients and only mentioned by patients when prompted 
by directive questions. In particular, the need to take abiraterone acetate on an 
empty stomach was not deemed problematic. Some differences in the patient 
experience (e.g. side effects) and HRQoL of patients receiving abiraterone acetate 
and enzalutamide were noted and warrant further exploration. cOnclusiOns: 
Patients and carers reported largely positive experiences with novel anti-androgen 
therapies for the treatment of mCRPC. Potential differences between regimens in 
terms of treatment satisfaction and HRQoL are currently being explored in a larger 
quantitative online study.
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ReduCiNg tHe BaRRieRS tO CaPtuRiNg PatieNt RePORted OutCOmeS iN 
ONCOlOgy StudieS
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Objectives: The FDA has previously noted that data reported directly by patients 
about how they are feeling and functioning (i.e. patient reported outcomes (PROs)) 
are rarely included in oncology drug labelling claims in the United States, with 
end points relating to survival, imaging and biomarkers tending to take priority. 
However, while research suggests an increase in PRO use in oncology trials, signifi-
cant challenges remain and a low burden solution for all stakeholders is becom-
ing increasingly important. MethOds: Key challenges for integrating PROs into 
oncology clinical trials were identified based on study protocols, sponsor feedback 
and best practices from previous oncology studies. Based on this feedback an elec-
tronic solution for capturing data in oncology studies was developed. Results: 
Patient and site burden were identified as key challenges in oncology studies 
deploying PROs. Oncology patients can be very impaired, so requiring the com-
pletion of lengthy questionnaires can result in non-compliance. A user focused 
electronic system reduces the burden of patients providing answers to question-
naires, and opens the possibility for data capture to occur at home rather than at 
study visits. Feedback also highlighted that sites struggle with organizing visits 
and staying protocol compliant. An electronic visit scheduling tool can help sites 
keep track of what order and at which visits questionnaires should be completed 
and to help remind and reschedule patient visits. cOnclusiOns: Obtaining a 
proper understanding of the patients experience in oncology clinical studies is 
increasingly becoming a priority for multiple stakeholders, not least the patients 
themselves. While there is evidence that the number of PROs being included in 
oncology studies is increasing over time there are still significant challenges to 
capturing high-quality PRO data. A holistic electronic solution, which considers 
both the patients and sites experience of providing data, can reduce the barriers 
to capturing high-quality PRO data.
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Objectives: Research on adherence, health outcomes and shared decision mak-
ing all highlight the importance of understanding patient treatment preferences. 
However, a recent systematic review (Shingler et al., 2014) showed how little work 
has explored treatment preferences of oncology patients. The aim of the present 
study was to identify issues from previous patient preference research in oncology 
to design a novel protocol to explore treatment preferences of men with metastatic 
prostate cancer. MethOds: It was hypothesised that the low number of reported 
studies in oncology may be due to methodological issues encountered in studies. 
A review of stated preference research completed in oncology identified different 
issues. This information was then used to design a protocol for a patient prefer-
ence study in men with metastatic castrate resistant prostate cancer. Results: 
Identified issues include (i) the use of inappropriate attributes (describing death, 
survival or progression), (ii) challenges with recruitment, sometimes associated 
symptoms, often painful and debilitating (Mughal et al. 2014). Developed from 
the widely used MPN-SAF, the 7-item MPN-SAF TSS was modified with word-
ing changes and by adding one tiredness item to better meet regulatory needs 
and assess symptom severity in myelofibrosis to support treatment benefit end-
points in clinical research. Study objectives were to translate the mMPN-SAF TSS 
into 21 languages for 26 countries and to assess comprehension and concep-
tual equivalence with the English source version in order to expand its use in 
global myelofibrosis research. MethOds: The mMPN-SAF TSS was translated 
following ISPOR guidelines for linguistic validation of PRO measures (Wild et 
al., 2005) using the universal approach (Wild et al., 2009). For each non-English 
language, two forward translations by native translators, reconciliation of for-
ward translations, back-translation by one English-speaker fluent in the target 
language, and final reconciliation by a native-speaking language coordinator 
were conducted. Harmonization (i.e., comparison between languages for con-
sistent interpretation) was performed to ensure conceptual equivalence across 
languages. Interviews were conducted with 4-5 native-speaking myelofibrosis 
patients for each language/country combination (N= 142). Interview data were 
analyzed qualitatively to assess linguistic and cultural validity in each language 
and confirm conceptual equivalence. Results: Mean age was 60 years (range 
25-88); 51% were male. The translations were well understood and considered 
relevant with some patients raising minor issues during interviews. Patient 
feedback resulted in wording changes to the Bulgarian, Czech, Danish, Dutch, 
German, Hebrew, Hungarian, Japanese, Korean, Malay, Russian, Spanish, Simplified 
and Traditional Chinese versions. cOnclusiOns: All translated versions of the 
mMPN-SAF TSS were confirmed to be conceptually equivalent and well understood 
in the 26 countries evaluated. These translations fill a significant need for patient-
focused instruments in local languages to facilitate future myelofibrosis research 
worldwide.
PCN235
tHe fiNNiSH veRSiONS Of tHe lOweR-limB SeCtiONS Of tHe tORONtO 
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Objectives: The Finnish language has no no function-related cancer-specific 
outcome measures. The authors translated the Toronto Extremity Salvage Score 
(TESS) and the Musculoskeletal Tumor Society (MSTS) into Finnish and pilot tested 
the versions. MethOds: Translation and transcultural adaptation was adhered to 
the guidelines of the International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR). Lower-limb TESS and MSTS outcome measures underwent 
forward-backward translation into Finnish. A multidisciplinary panel reviewed 
the process and proposed pre-final Finnish versions. Between March and May 
2015, altogether 18 consecutive patients who had undergone limb-sparing surgery 
for lower extremity soft tissue sarcoma (STS) visited the outpatient clinic of the 
Helsinki University Hospital Department of Oncology and completed the TESS, 
while simultaneously undergoing clinical assessment with the MSTS. Participants 
were interviewed to reveal problems in the translations. Results: The transla-
tion process revealed minor cultural differences between the translations of the 
TESS, which required adjustments. The MSTS translated well. After evaluating the 
measurement outcomes, the median TESS and MSTS scores were 85.5% (range, 
51.5-100.0%) and 76.7% (range, 26.7-100.0%), respectively. In both outcome meas-
ures, the authors noted a 5% ceiling effect. cOnclusiOns: The pilot testing of the 
Finnish translation of the lower-limb TESS and MSTS indicated a good functional 
outcome in most patients who underwent lower limb-sparing surgery for STS. 
The TESS and the MSTS measurement outcomes correlated relatively closely. The 
psychometric properties of the Finnish versions of the lower-limb TESS and MSTS 
warrant further studying.
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Objectives: Receiving chemotherapy causes moderate to severe adverse events 
which deteriorate to both body and mind of breast cancer patients. Some ques-
tionnaires were developed to measure breast cancer patients’ quality of life e.g., 
the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-
C30, the Functional Assessment of Cancer Therapy for Breast cancer (FACT-B). 
Howereve, those questionnaires were rarely used in routine practice due to time 
consuming in difficulty in outcome evaluation. Therefore, we need to develop 
the practical questionnaire to evaluate impacts of chemotherapy on the overall 
health status in breast cancer patients’ view. MethOds: We develop the ques-
tionnaire focusing on the symptoms related to adverse reaction of chemotherapy 
which patients felt and correlate with activity of daily living. The questionnaire 
consisted of 16 items for patients to answer with 5 likert scale (strongly disagree 
0 to strongly agree 4). The possible highest score were 64 and the higher score was 
the more suffering from chemotherapy in patients’ perspective. Results: One 
hundred breast cancer patients were interviewed. The average interview time was 
only 5-10 minutes per patient. Average age of patients were 52.09 ±12.77 years old 
and majority of them (71%) had stage I to III breast cancer. The average score was 
23.06 + 13.27 (minimum score was 0 and maximum score was 57 out of 64). we 
found the highest score (2.32 + 1.67) that patient reported for impacts on their 
heath from chemotherapy was “I am tried easier” and the lowest score (0.56 + 1.21) 
patient reported was “it is hard to breathe”. The factors associated with total score 
of questionnaire were adverse reactions. cOnclusiOns: Our questionnaire can 
be used as a screening tool to classify patients according to severity and urgency 
for providing pharmaceutical care especially in the practice sites with limited 
manpower of clinical pharmacists.
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urement of hope and 639 abstracts on the measurement of psychological func-
tion in cancer were screened to identify publications focusing on the development 
of psychological instruments. In some cases, an article describing a promising 
instrument was selected and then used to identify the original validation study 
which was then substituted as the article selected for full text review. 16 measures 
with a hope focus or hope-specific items were identified for further review and 9 
measures of positive psychological constructs developed for use in the context of 
cancer were identified for further review. cOnclusiOns: Positive psychological 
constructs factor into cancer treatment and symptom remission. Measurement of 
these domains is an important component of treatment selection and outcomes 
assessment. However, reliable and valid assessment of hope and related constructs 
depends on the availability of psychometrically sound instruments developed for 
this context of use. The present study demonstrates that while much work has 
been done in research settings to develop such measures, there is still a need for 
further refinement and development of these tools so that they are fit for use in a 
regulated research context.
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Objectives: Overall aim of this study is to evaluate acceptability and usability of 
the Quality of Life-Portal (QOL-Portal), developed for breast cancer patients. The 
portal is designed for assessing information needs and patient’s QOL and enhanc-
ing patient education as well as health literacy. MethOds: Software development 
has been done in close collaboration with a multidisciplinary group of healthcare 
professionals following an Extreme Programming approach. This means that soft-
ware development was based on an stepwise process that included the evaluation 
of individual components of the portal by healthcare professionals and subsequent 
adaptation in accordance with the provided feedback. Currently, we are conduct-
ing semi-structured interviews in breast cancer patients to collect information 
on acceptability and usability of the QOL-Portal. The main evaluation criteria are 
divided into usability (e.g. possible problems with web-access, user-friendliness and 
satisfaction) and content (e.g. understandability of information and of graphical 
questionnaire presentation). Results: Software development has been completed 
and resulted in an online QOL portal for breast cancer patients. Based on feedback 
from healthcare professionals we developed several components for the portal: an 
information module to enhance patients’ condition and treatment related knowl-
edge, health literacy, a symptom monitoring tool based on the EORTC questionnaires 
(allowing assessments in the hospital and at home), and a basic set of self-help 
interventions. In addition, the portal provides graphical feedback on the QOL results 
to patients themselves. Preliminary results from the ongoing patient interviews will 
be presented at the conference. cOnclusiOns: QOL-Portals are gaining importance 
as they allow routine symptom assessment and provide important information to 
patients and medical alike. We have developed key components for the portal which 
undergo further adaption and improvement based on feedback from healthcare 
professionals and patients. In a next step, we will evaluate the impact of the portal 
on patients’ QOL.
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Objectives: Oral chemotherapy was developed to reduce in-patient stays while 
providing the same level of efficacy and safety. This study assessed the health-
related quality of life (HRQoL) of patients treated with oral vinorelbine for metastatic 
NSCLC and their caregivers. MethOds: This longitudinal survey assesses 2 visits 
documenting the second and third chemotherapy cycles. Patients had metastatic 
NSCLC and received oral vinorelbine (day 1 and 8 of 3-week cycles) and carboplatin 
(day 1). Baseline measures included demographics, anamnesis, co-morbidities and 
current treatment. SF-12 was reported at the end of each cycle, on the patients 
and interestingly on the caregivers. Results: Three Danish centers included 45 
patients: median age: 66.9 y.o., 53.3% were male. Performance status (ECOG) was 
0: 33.3%; 1: 51.1%; 2+: 15.6%. Main reason for choosing oral vinorelbine was con-
venience. Caregivers, mainly spouses (76.7%), were 57.8 y.o. No major change on 
SF-12 scores was reported between cycle 2 and 3. Physical summary scores (PCS) of 
patients (37.0-38.6, respectively cycle 2 and 3) were lower than those of caregivers 
(52.9-53.4) and general population (44). Mental summary scores (MCS) of patients 
(47.7-44.2) and caregivers (46.2-44.6) were much lower than those one of a popula-
tion of same age (patient: 52; caregiver: 51). The most affected patient scores were 
physical functioning (40.4), role physical (40.1), vitality (37.2). Social functioning (SF) 
was similarly high in patients and caregivers (76.9 vs. 78.9, patient vs. caregiver) 
while mental health of both patients and caregivers were lower (66.7 vs. 65.5) than 
SF. cOnclusiOns: Metastatic NSCLC deeply affects patients’ HRQoL as measured 
by a generic instrument, both on MCS and PCS. Caregivers’ HRQoL is also affected, 
mainly on MCS. Patients receiving oral vinorelbine plus carboplatin and their car-
egivers maintain a good level of social functioning.
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with the use of a single approach (such as a single centre), (iii) the health state of 
the participant, and (iv) the burden on site staff affecting recruitment. The protocol 
addresses issue (i) by describing effectiveness in terms of time to need for new 
treatment rather than disease progression as well as cognitive debriefing; issues 
ii & iv using a broad spectrum of recruitment methods; (iii) minimising patient 
burden. cOnclusiOns: The development of this protocol has been informed by 
lessons learnt from previous research. An analysis of the issues identified as limita-
tions in previous studies in collecting patient preference data allows improvements 
in protocol design.
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Objectives: Patient-reported outcomes (PRO) provide a more comprehensive pic-
ture of patients’ quality of life than do mere physicians’ ratings. Electronic data 
collection of PRO offers several advantages and allows assessments at patients’ 
homes as well. This study reports on patients’ internet use, their attitudes towards 
electronic and web-based PRO assessment (clinic-ePRO and home-ePRO) and the 
feasibility of these two assessment modes. MethOds: At the Medical University 
of Innsbruck and Kufstein County Hospital, cancer patients who participated in 
clinic-ePRO/home-ePRO were asked to complete a comprehensive evaluation form 
on their internet usage, attitudes towards and the feasibility of routine clinic-
ePRO/home-ePRO with the Computer-based Health Evaluation System (CHES) 
software. Results: In total, 158 patients completed the evaluation form. Most 
patients expressed willingness to complete routine clinic-ePRO (92.3%)/home-
ePRO (70%) assessments in the future and to discuss such data with attending 
physicians (82.2%). The CHES software for home-ePRO was preferred over phone 
interviews by 95.7% of patients and 72.7% experienced it as easy to use. Only a few 
minor suggestions for improvement were made. Overall satisfaction with home-
ePRO was high with an average rating of 9.1 points (range 5-10 points). However, 
there became an age bias apparent, as participating patients were approximately 
ten years younger than those refusing clinic-ePRO/home-ePRO. cOnclusiOns: 
The use of clinic-ePRO/home-ePRO was in general shown to be feasible and well 
accepted. However, to be more inclusive in the implementation of clinic-ePRO/
home-ePRO, educational programs concerning their particular benefit in oncology 
practice potentially could enhance patients’ attitudes towards, and consequently 
their acceptance of and compliance with electronic PRO assessments.
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Objectives: To investigate the effects of adverse events on quality of life (QOL) scores 
during adjuvant chemotherapy for breast cancer patients. MethOds: We analyzed 
the QOL scores assessed by EQ-5D and the worst grades of adverse events assessed 
by the National Cancer Institute - Common Toxicity Criteria(NCI-CTC) Version 2.0 
collected from a national multicenter phase III randomized clinical trial: National 
Surgical Adjuvant Study of Breast Cancer-02 (N-SAS BC 02), which compared two 
types of taxane-containing chemotherapy, as an approved sub analysis numbered 
CSP-HOR22. A linear regression model was constructed with change in EQ-5D score 
as an objective variable, calculated as the worst scores minus the baseline (before 
chemotherapy) scores, and the incidences of adverse events as independent vari-
ables, set as binary variables regardless of grade. Results: From 300 participants, 
250 complete series of data of EQ-5D scores and adverse events were extracted. The 
average baseline EQ-5D score was 0.798. The average of worst EQ-5D scores for each 
participant during chemotherapy was 0.720 and the average change in EQ-5D score 
was -0.078, with a range of -0.619 to +0.464. Although QOL deteriorated in 140 patients, 
it improved in 54 patients. Seventeen adverse events were selected as independent 
variables excluding rare ones. The following three coefficients of the regression model 
were significant; edema: -0.056 (p= 0.03), phlebitis: 0.068 (p= 0.01), and sensory nerve 
disturbance: -0.084 (p< 0.01), and these results are equivalent to simple linear regres-
sion models for each factor. cOnclusiOns: Cases of QOL improvement events may 
have reduced the model’s descriptive power and caused a positive coefficient value. 
Since patients treated with taxane-containing chemotherapy often suffer sensory 
nerve disturbance as well as edema for a longer period, even after the termination 
of chemotherapy, clinicians should provide selective care to avoid deterioration of 
patients’ QOL.
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Objectives: To understand the ways in which hope and related constructs are 
applied and measured in the context of healthcare, especially in patients with 
cancer. Targeted literature reviews were conducted in two areas: (1) Psychological 
assessments measuring hope, and (2) Measures of psychological function in 
cancer-related care, including well-being and other positive psychological con-
structs. MethOds: To better understand the scope of psychological assessments 
developed and currently in use to measure hope and related positive psychological 
constructs in the context of healthcare, a targeted review of the published literature 
was undertaken. MEDLINE and PsychINFO database searches were conducted for 
publications in English in the past 5 years. Results: 876 abstracts on the meas-
